We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KEY:NYSEKeyCorp Analysis

Data as of 2026-05-20 - not real-time

$20.92

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

KeyCorp trades around $20.92, sitting below its 20‑day SMA of $21.58 and facing a bearish MACD histogram, while the RSI of 43 suggests neutral momentum. Volume is increasing and the 30‑day volatility of roughly 21% combined with a beta near 1.0 points to market‑aligned risk, yet the stock remains above the identified support of $20.69 and below the resistance at $22.43. Fundamentally, the bank delivered a 12% revenue increase YoY and a striking 33% EPS jump, beating expectations and prompting analysts to upgrade to a "buy" consensus with a median target of $24. The dividend yield of 3.9% and a 50% payout ratio are supported by robust operating cash flow, indicating sustainability. However, the DCF fair‑value estimate of $17.15 places the current price in a slight premium, while a PE of 12.8 is well under the industry average of 16.5, suggesting a mixed valuation picture.
Strategic moves such as the acquisition of Clearwater UK and a potential Moody's rating upgrade broaden geographic exposure and could enhance the middle‑market M&A franchise, providing a catalyst for upside. The combination of solid dividend income, growth‑oriented earnings, and a favorable analyst outlook outweighs the moderate sector and regulatory risks, positioning KeyCorp as a compelling hold‑to‑buy opportunity across medium to long horizons.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below short‑term SMA and bearish MACD signal
  • Neutral RSI and proximity to support level
  • Increasing volume but limited upside in near term

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Earnings beat with strong revenue and EPS growth
  • Analyst consensus "buy" with median target $24
  • High dividend yield and sustainable payout

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Strategic European acquisition expanding M&A franchise
  • Potential Moody's rating upgrade improving credit perception
  • Blend of value metrics (low PE) and growth prospects

Key Metrics & Analysis

Financial Health

Revenue Growth11.80%
Profit Margin27.02%
P/E Ratio12.8
ROE9.98%
ROA1.03%
P/B Ratio1.3
Op. Cash Flow$2.3B
Industry P/E16.5

Technical Analysis

TrendBullish
RSI42.9
Support$20.69
Resistance$22.43
MA 20$21.59
MA 50$20.85
MA 200$19.82
MACDBearish
VolumeIncreasing
Fear & Greed Index89.18

Valuation

Fair Value$17.15
Target Price$24.97
Upside/Downside19.38%
GradeFair
TypeBlend
Dividend Yield3.92%

Risk Assessment

Beta1.04
Volatility21.49%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.